CETP inhibitors reduce transfer of cholesterol from HDL-C particles to LDL-C and VLDL-C, resulting in increased HDL-C levels and reduction in LDL-C and Apo B. The initial realization that CETP inhibition may assist in treatment and prevention of CAD originated from the discovery in 1990 that genetic CETP deficiency led to markedly increased levels of HDL-C and a strong inverse relationship with prevalence of CAD [15]. Here, APOB is linked to coronary artery disorder.